Parp1 inhibitor

Show results for

Unknown (460)
Transcriptomics (96)
Genomics (95)
Proteomics (48)
Metabolomics (4)
Other (3)
Clinical (1)
Methylation profiling (1)

Organisms

Homo sapiens (120)
Aerococcus urinae NBRC 15544 = CCUG 36881 (38)
Andropogon gerardi (38)
Bacteria (38)
Bartonella quintana JK 31 (38)
Canis lupus familiaris (38)
Cnidaria (38)
Ectopseudomonas oleovorans CECT 5344 (38)
Ensifer adhaerens (38)
Halictus scabiosae (38)
Human immunodeficiency virus 1 (38)
Mesocricetus auratus (38)
Miscanthus x giganteus (38)
Morchella importuna (38)
Mus musculus (38)
Panicum virgatum (38)
Pseudomonas aeruginosa PA103 (38)
Pseudomonas aeruginosa SJTD-1 (38)
Rabies virus Nishigahara RCEH (38)
Rattus norvegicus (38)
Rattus rattus (38)
Rhodococcus jostii RHA1 (38)
Rhodopseudomonas palustris (38)
Shigella (38)
Sorghastrum nutans (38)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (38)
Mus musculus (13)
Rattus norvegicus (5)
Drosophila melanogaster (1)
Arabidopsis thaliana (1)

Organisms

Homo sapiens (42)
Rattus norvegicus (4)
Mus musculus (2)
Caenorhabditis elegans (1)
Sus scrofa (1)

Repository

biostudies-arrayexpress (75)
ENA (63)
geo (45)
pride (38)
EGA (12)
iProX (6)
MetaboLights (4)
jPOST (2)
MassIVE (2)

Tissue

Cell culture (15)
Epithelial cell (6)
Permanent cell line cell (4)
Lung neuroendocrine cell (3)
Ovarian surface epithelial cell (3)
Kidney (2)
Blood (1)
Bone marrow cell (1)
Breast epithelium (1)
Cell line cell (1)
Colon (1)
Early embryonic cell (1)
Egg (1)
Fibroblast (1)
Hippocampus (1)
Lung (1)
Mesenchymal cell (1)

Disease

Malignant neoplasm of ovary (5)
Lung small cell carcinoma (3)
Lung adenocarcinoma (2)
Prostatic Neoplasms (1)
Breast cancer (1)
Breast cancinoma (1)
Chronic myeloid leukemia (1)
Colon cancer (1)
Idiopathic pulmonary fibrosis (1)
Neuroblastoma (1)
Pancreas adenocarcinoma (1)
Peripheral primitive neuroectodermal tumor (1)

Technology Type

Mass Spectrometry (38)
Affinity purification coupled with mass spectrometry proteomics (20)
Shotgun proteomics (12)
Bottom-up proteomics (8)
Data-dependent acquisition (4)
NMR spectroscopy (2)
Mass spectrometry assay (2)
Data-independent acquisition (2)
ILLUMINA, Illumina HiSeq 2500 (1)
Illumina HiSeq 2000 (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (2)
Bruker (2)
Liquid Chromatography MS - positive - hilic (2)
Affymetrix Whole Transcript (1)
Illumina HiSeq 2500 (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 4000 (1)
NextSeq 500 (1)
Q Exactive HF (1)
Q Exactive HF-X (1)
Liquid Chromatography MS - negative - hilic (1)

Publication Date

2025 (21)
2022 (19)
2014 (19)
2026 (18)
2024 (14)
2016 (9)
2012 (9)
2015 (8)
2013 (8)
2017 (7)
2010 (7)
2021 (7)
2018 (6)
2023 (5)
2008 (5)
2019 (4)
2011 (3)
2020 (2)
2009 (1)

CHEBI ID

CHEBI:48430 (2)
CHEBI:16264 (2)
CHEBI:17287 (2)
CHEBI:18132 (2)
CHEBI:15846 (2)
CHEBI:16856 (2)
CHEBI:16870 (2)
CHEBI:16977 (2)
CHEBI:17924 (2)
CHEBI:15428 (2)
CHEBI:17268 (2)
CHEBI:17196 (2)
CHEBI:18019 (2)
CHEBI:15891 (2)
CHEBI:18050 (2)
CHEBI:16857 (2)
CHEBI:17053 (2)
CHEBI:16015 (2)
CHEBI:15422 (2)
CHEBI:18012 (2)
CHEBI:16027 (2)
CHEBI:16919 (2)
CHEBI:16414 (2)
CHEBI:17191 (2)
CHEBI:15603 (2)
CHEBI:16643 (2)
CHEBI:17895 (2)
CHEBI:17295 (2)
CHEBI:16828 (2)
CHEBI:14649 (1)

Metabolite Name

Adenosine triphosphate (2)
2-Aminoadipate (1)
Nmn (1)
Deamido-NAD (1)
UDP-N-Acetylglucosamine (1)
D-Glucitol (1)
Nicotinate D-ribonucleotide (1)
2-Oxoisocaproate (1)
L-isoleucine (1)
4-Methyl-2-oxovaleric acid (1)
Nicotinamide Riboside (1)
Choline glycerophosphate (1)
O-Phosphocholine (1)
1-methylguanidine (1)
L-Aspartate (1)
Adenosine 5'-monophosphate (1)
L-leucine (1)
L-Lactic acid (1)
Formate (1)
Creatine phosphate (1)
Glutathione (1)
Sn-Glycero-3-phosphocholine (1)
Adenosine diphosphate ribose (1)
1-Methylnicotinamide (1)
Pyruvic acid (1)
D-Glucose (1)
3-Methyl-2-oxovaleric acid (1)
Beta-Alanine (1)
Glycine (1)
UDP-GlcNAc (1)

First Public Date

2025 (16)
2026 (15)
2022 (10)
2023 (6)
2024 (4)
2020 (2)
2019 (2)
2018 (2)
2014 (2)
2021 (1)
2017 (1)
2016 (1)
2015 (1)

Study status

Recruiting (1)

Study type

Transcription profiling by array (53)
ChIP-seq (7)
RNA-seq of coding RNA (5)
ChIP-chip by tiling array (3)
Genotyping by array (3)
Unknown experiment type (1)
Other (1)
DNA-seq (1)
Methylation profiling by array (1)
Interventional (1)

Release Date

2022 (58)
2023 (50)
2020 (50)
2025 (49)
2024 (42)
2021 (42)
2014 (35)
2019 (35)
2017 (32)
2018 (31)
2016 (30)
2015 (15)
2013 (13)
2012 (11)
2026 (11)
2010 (10)
2011 (9)
2008 (8)
2009 (1)
2007 (1)
2006 (1)

Lab affiliation

Moffitt Cancer Center Tampa, FL, USA (8)
Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark (3)
1State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China 2Department of Biochemistry and Molecular Biology, School of Life Sciences, Peking University, Beijing, China, Peking University, Beijing 100871, China (2)
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, 75390, TX, USA (2)
1Department of Medicine, University of Minnesota, 420 Delaware Street, SE, Minneapolis, Minnesota 55455, USA (1)
Cell and Chemical Biology Leiden University Medical Center The Netherlands (1)
Center for Diagnostics, Section Mass Spectrometry and Protemics, University Medical Center Hamburg-Eppednorf, Hamburg, Germany (1)
Centre de recherche du CHU de Québec - Université Laval (1)
Department of Anatomy and Cell Biology Faculty of Medicine and Health Science Université de Sherbrooke (1)
Department of Biochemistry and Biophysics, University of Pennsylvania (1)
Department of Biochemistry and Molecular Biology Charbonneau Research Institute Cummings School of Medicine University of Calgary (1)
Department of Internal Medicine I, Center of IntegratedOncology, Cologne-Bonn Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne (1)
Department of Life Science, Pohang University of Science and Technology, Pohang, Gyeongbuk, Korea Department of Integrative Biosciences & Biotechnology, Pohang, Gyeongbuk, Republic of Korea (1)
Department of Molecular Mechanisms of Disease, University of Zurich, CH-8057 Zurich, Switzerland (1)
Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine or College of Pharmacy, Seoul National University, Republic of Korea (1)
Department of Molecular Pharmacology and Therapeutics Columbia University Irving Medical Center (1)
Department of human molecular genetics and biochemistry, Sackler faculty of medicine, Tel Aviv University, Israel. (1)
Drug Discovery Moffitt Cancer Center Tampa, FL, USA (1)
Institute of Translational Medicine, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, School of Medicine, Zhejiang University, Zhejiang, China. (1)
Key Laboratory of Molecular Epigenetics of Ministry of Education (MOE), Northeast Normal University, Changchun, China. (1)
Lunenfeld-Tanenbaum Research Institute and Department of Molecular Genetics, University of Toronto, Toronto, ON M5G 1X5, Canada (1)
Mass Spectrometry/Proteomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands (1)
Novo Nordisk Foundation Center for Protein Research, Proteomics program, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark (1)
Sichuan University; Chengdu University (1)
Sir run run shaw hospital (1)
Tumor biology, Oncology Research Unit, Pfizer (1)
University of California San Francisco (1)

Location

China (1)

Keyword

Poly(ADP-ribose) polymerase-1 inhibitor (1)
HS-10502 (1)
Prostate Cancer, Colorectal Cancer (1)

Previous page
1 / 71
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 71
Next page

Sort by:

Relevance

Page size

Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights

The Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells

Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...

2016-11-07 | MTBLS337 | MetaboLights

Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks

The project is about studying the dynamics of PARP1 when bound to DNA and veliparib derivatives.

ORGANISM(S): Homo sapiens (Human)

2024-03-19 | PXD047072 | Pride

PARP1 auto-modification promotes faithful Okazaki fragment processing and limits replication fork speed

Poly(ADP-ribose) polymerase (PARP) inhibitors have proven their efficacy for treating tumors defective in homologous recombination via synthetic lethality. In response to DNA breaks, PARP1 is the primary ADP-ribosylation writer, modifying itself (auto-modification) and other proteins to facilitate r...

ORGANISM(S): Homo sapiens (Human)

2025-10-02 | PXD066033 | Pride

Parp1 Ptm Okazaki fragment Adp-ribosylation Dna replication

Notch/HES1-mediated PARP1 activation: A cell-type specific mechanism for tumor suppression

Notch signaling plays both oncogenic and tumor suppressor roles, depending on cell type. In contrast to T cell acute lymphoblastic leukemia (T-ALL), where Notch activation promotes leukemogenesis, induction of Notch signaling in B-ALL leads to growth arrest and apoptosis. The Notch target Hairy/Enha...

ORGANISM(S): Homo sapiens

2011-12-12 | E-GEOD-26366 | biostudies-arrayexpress

PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib

The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors. PARPis also demonstrate activity in non-BRCA mutated tumors presumably through induction of PARP1-DNA trapping. Despit...

ORGANISM(S): Homo sapiens (Human)

2022-07-08 | PXD033530 | Pride

Parp1 Drug resistance Talazoparib

PARP1 auto-modification promotes faithful Okazaki fragment processing and limits replication fork speed

ORGANISM(S): Homo sapiens (Human) Xenopus laevis (African clawed frog)

2025-10-02 | PXD052191 | Pride

Okazaki fragment processing Parp1 Dna repair Af1521 macrodomain Adp-ribosylation Xenopus egg extract Auto-modification Dna replication

PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib (scRNA-Seq)

PRJNA836116 | ENA

PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib (RNA-Seq)

PRJNA836117 | ENA

PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib (ATAC-Seq)

PRJNA836115 | ENA

Previous page
1 / 71
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 71
Next page

Sort by:

Relevance

Page size

708 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets